FDA’s Priority Review Acceptance for Giredestrant NDA Sets a November 2026 Decision Clock for the Adjuvant SERD Market
FDA accepted Roche's giredestrant NDA under Priority Review on June 2, 2026—targeting a November 2026 action date for the...
giredestrant
Roche’s Giredestrant ASCO Play Is a Signal to Every Endocrine Therapy Competitor
Roche's giredestrant lidERA data at ASCO 2026 targets early breast cancer across menopause status — and the $4.3B aromatase...